Cleared Traditional

K101763 - DIOPSYS NOVA VEP VISION TESTING SYSTEM

K101763 is an FDA 510(k) clearance for DIOPSYS NOVA VEP VISION TESTING SYSTEM, manufactured by Diopsys, Inc.. The device is a Class 2 Neurology device with product code GWE cleared through the Traditional 510(k) pathway after a 320-day FDA review.

K101763 · Diopsys, Inc. · Neurology device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
May 2011
Decision
320d
Days
Class 2
Risk

K101763 is an FDA 510(k) clearance for the DIOPSYS NOVA VEP VISION TESTING SYSTEM. Classified as Stimulator, Photic, Evoked Response (product code GWE), Class II - Special Controls.

Submitted by Diopsys, Inc. (Pine Brook, US). The FDA issued a Cleared decision on May 9, 2011 after a review of 320 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1890 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

FDA 510(k) Submission Details - K101763

510(k) Number K101763 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 23, 2010
Decision Date May 09, 2011
Days to Decision 320 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
171d slower than avg
Panel avg: 149d · This submission: 320d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GWE Device Classification - Class 2, Special Controls

Product Code GWE Stimulator, Photic, Evoked Response
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1890
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GWE Stimulator, Photic, Evoked Response

All 43
Devices cleared under the same product code (GWE) and FDA review panel - the closest regulatory comparables to K101763.
RETeval Visual Electrodiagnostic Device
K142567 · Lkc Technologies, Inc. · May 2015
ADHERENT VISUAL STIMULATOR GOGGLES
K113785 · Anschel Technology, Inc. · Jun 2012
VISIONSEARCH 1
K120104 · Visionsearch Pty, Ltd. · May 2012
LIFELINES PHOTIC STIMULATOR
K101691 · Lifelines , Ltd. · Aug 2010
NEUCODIA
K081591 · Verisci Corporation · May 2009
GLAID OCULAR ELECTROPHYSIOLOGY DEVICE
K043367 · Lace Electronica S.R.L. · Nov 2005
K101763 · DIOPSYS NOVA VEP VISION TESTING SYSTEM
Download PDF FDA Summary Diopsys, Inc.